ANEB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANEB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Anebulo Pharmaceuticals's Enterprise Value is $69.86 Mil. Anebulo Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.58 Mil. Therefore, Anebulo Pharmaceuticals's EV-to-FCF for today is -7.29.
The historical rank and industry rank for Anebulo Pharmaceuticals's EV-to-FCF or its related term are showing as below:
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-05), Anebulo Pharmaceuticals's stock price is $2.95. Anebulo Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.420. Therefore, Anebulo Pharmaceuticals's PE Ratio for today is At Loss.
The historical data trend for Anebulo Pharmaceuticals's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anebulo Pharmaceuticals Annual Data | |||||||||
Trend | Jun20 | Jun21 | Jun22 | Jun23 | |||||
EV-to-FCF | - | -28.58 | -19.65 | -5.06 |
Anebulo Pharmaceuticals Quarterly Data | ||||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-FCF | Get a 7-Day Free Trial | -5.65 | -6.81 | -5.06 | -6.73 | -5.86 |
For the Biotechnology subindustry, Anebulo Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Anebulo Pharmaceuticals's EV-to-FCF falls into.
Anebulo Pharmaceuticals's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 69.858 | / | -9.581 | |
= | -7.29 |
Anebulo Pharmaceuticals's current Enterprise Value is $69.86 Mil.
Anebulo Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anebulo Pharmaceuticals (NAS:ANEB) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Anebulo Pharmaceuticals's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 2.95 | / | -0.420 | |
= | At Loss |
Anebulo Pharmaceuticals's share price for today is $2.95.
Anebulo Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Bimal R. Shah | director | C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTER AVENUE, SUITE 240, HENDERSON NV 89052 |
Richard Anthony Cunningham, | director, officer: Chief Executive Officer | ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139 |
Dan George | officer: Chief Financial Officer | 1412 62ND STREET, EMERYVILLE CA 94608 |
Sandra A. Gardiner | officer: Acting Chief Financial Officer | CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Kenneth C Cundy | officer: Chief Scientific Officer | 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025 |
Nathaniel Calloway | director | C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734 |
Simon Allen | director, officer: Chief Executive Officer | C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037 |
Aron R. English | director, 10 percent owner | 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107 |
Kenneth Lin | director | PO BOX 1005, LOS ALTOS CA 94022 |
Karah Herdman Parschauer | director | 60 LEVERONI COURT, NOVATO CA 94949 |
22nw Fund, Lp | 10 percent owner | 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107 |
Joseph F. Lawler | director, 10 percent owner | 2110 RANCH ROAD 620 S, #341732, LAKEWAY TX 78734 |
Areta Kupchyk | director | C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734 |
Jason Aryeh | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
22nw, Lp | 10 percent owner, other: See Explanation of Response | 590 1ST AVE S, UNIT C1, SEATTLE WA 98104 |
From GuruFocus
By Business Wire • 10-06-2023
By Business Wire • 09-20-2023
By Business Wire • 10-06-2023
By Business Wire Business Wire • 08-12-2021
By Business Wire • 08-30-2023
By Business Wire Business Wire • 01-03-2022
By Business Wire Business Wire • 01-06-2022
By Business Wire Business Wire • 10-05-2021
By Business Wire Business Wire • 05-11-2022
By Business Wire • 11-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.